CN109355269B - 鞘氨醇激酶1及其融合蛋白及其用途 - Google Patents

鞘氨醇激酶1及其融合蛋白及其用途 Download PDF

Info

Publication number
CN109355269B
CN109355269B CN201811225720.2A CN201811225720A CN109355269B CN 109355269 B CN109355269 B CN 109355269B CN 201811225720 A CN201811225720 A CN 201811225720A CN 109355269 B CN109355269 B CN 109355269B
Authority
CN
China
Prior art keywords
leu
val
pro
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811225720.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109355269A (zh
Inventor
段海峰
解晶
胡显文
弓景波
薛冰华
张群伟
肖秀孝
崔美兰
庞如梦
王瑞
于婷婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Shuangyin Biotechnology Co ltd
Original Assignee
Beijing Shuangyin Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Shuangyin Biotechnology Co Ltd filed Critical Beijing Shuangyin Biotechnology Co Ltd
Priority to CN201811225720.2A priority Critical patent/CN109355269B/zh
Publication of CN109355269A publication Critical patent/CN109355269A/zh
Priority to PCT/CN2019/107091 priority patent/WO2020082950A1/zh
Priority to JP2021523243A priority patent/JP2022512843A/ja
Priority to US17/286,445 priority patent/US20210388326A1/en
Application granted granted Critical
Publication of CN109355269B publication Critical patent/CN109355269B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01091—Sphinganine kinase (2.7.1.91)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201811225720.2A 2018-10-21 2018-10-21 鞘氨醇激酶1及其融合蛋白及其用途 Active CN109355269B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201811225720.2A CN109355269B (zh) 2018-10-21 2018-10-21 鞘氨醇激酶1及其融合蛋白及其用途
PCT/CN2019/107091 WO2020082950A1 (zh) 2018-10-21 2019-09-20 鞘氨醇激酶1及其融合蛋白及其用途
JP2021523243A JP2022512843A (ja) 2018-10-21 2019-09-20 スフィンゴシンキナーゼ１とその融合タンパク質およびその使用
US17/286,445 US20210388326A1 (en) 2018-10-21 2019-09-20 Sphingosine kinase 1 and fusion protein comprising the same and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811225720.2A CN109355269B (zh) 2018-10-21 2018-10-21 鞘氨醇激酶1及其融合蛋白及其用途

Publications (2)

Publication Number Publication Date
CN109355269A CN109355269A (zh) 2019-02-19
CN109355269B true CN109355269B (zh) 2020-03-24

Family

ID=65345959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811225720.2A Active CN109355269B (zh) 2018-10-21 2018-10-21 鞘氨醇激酶1及其融合蛋白及其用途

Country Status (4)

Country Link
US (1) US20210388326A1 (https=)
JP (1) JP2022512843A (https=)
CN (1) CN109355269B (https=)
WO (1) WO2020082950A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109355269B (zh) * 2018-10-21 2020-03-24 北京双因生物科技有限公司 鞘氨醇激酶1及其融合蛋白及其用途
CN111303298B (zh) * 2020-02-19 2023-03-21 李瑛� 含有磷酸酶的融合蛋白及其产品和应用
CN112143705B (zh) * 2020-09-23 2022-09-06 北京华奥玄德生物医药科技有限公司 一种双基因修饰的干细胞及其用途
CN114762724A (zh) * 2020-12-31 2022-07-19 吴伯骥 HrpWEch蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114762723A (zh) * 2020-12-31 2022-07-19 吴伯骥 HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN112675293A (zh) * 2020-12-31 2021-04-20 吴伯骥 HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1228221A2 (en) * 1999-10-28 2002-08-07 Warner-Lambert Company Human sphingosine kinase gene
CN107875398A (zh) * 2017-09-27 2018-04-06 浙江大学 一种抗体偶联药物的制备方法、抗体偶联药物及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
WO2004061107A1 (ja) * 2002-12-27 2004-07-22 The New Industry Research Organization スフィンゴシンキナーゼ２を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット
WO2014135984A2 (en) * 2013-03-07 2014-09-12 Recopharma Ab Glycosylated mucin-immunoglobulin fusion protein coated device
JP6324137B2 (ja) * 2014-03-24 2018-05-16 ジヤトコ株式会社 シール機構付き車両用無段変速機
CN106279430B (zh) * 2015-06-30 2017-11-28 安源医药科技（上海）有限公司 Exendin‑4类似物融合蛋白及其制备方法和用途
CN106432511A (zh) * 2016-09-29 2017-02-22 上海凯茂生物医药有限公司 GLP‑1类似物‑Fc融合蛋白及其制备方法和用途
CN109355269B (zh) * 2018-10-21 2020-03-24 北京双因生物科技有限公司 鞘氨醇激酶1及其融合蛋白及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1228221A2 (en) * 1999-10-28 2002-08-07 Warner-Lambert Company Human sphingosine kinase gene
CN107875398A (zh) * 2017-09-27 2018-04-06 浙江大学 一种抗体偶联药物的制备方法、抗体偶联药物及应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
immunoglobulin heavy chain, constant region, partial [Homo sapiens];CAA04843.1;《GenBank》;20160724;全文 *
Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic β-cell death in diet-induced obese mice;Qi Y等;《The FASEB Journal·Research Communication》;20130719;第27卷(第10期);全文 *
sphingosine kinase 1 isoform 3[Homo sapiens];NP_001136073.1;《GenBank》;20180212;序列和相关信息 *
鞘氨醇激酶-1的乙酰化修饰及在糖尿病防治中的作用研究;于红阳;《中国博士学位论文全文数据库》;20130515;全文 *
鞘氨醇激酶在糖代谢调控中的作用研究;马萌萌;《中国博士学位论文全文数据库》;20090415;摘要、第19-87页 *

Also Published As

Publication number Publication date
JP2022512843A (ja) 2022-02-07
US20210388326A1 (en) 2021-12-16
CN109355269A (zh) 2019-02-19
WO2020082950A1 (zh) 2020-04-30

Similar Documents

Publication Publication Date Title
CN109355269B (zh) 鞘氨醇激酶1及其融合蛋白及其用途
US6509173B1 (en) Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US7227005B1 (en) Vascular endothelial growth factor 2
US6486301B1 (en) Interleukin-20
CA2296762A1 (en) Interleukin-20
AU736289B2 (en) A tumor necrosis factor related ligand
CN109796535A (zh) 靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
US20170081387A1 (en) Fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof
CN108220228A (zh) 无血清细胞培养基及高效表达重组蛋白质的方法
CN101633933A (zh) 表达抗体或抗体类似物的重组克鲁维酵母菌及其构建方法与应用
CA2295326A1 (en) Cardiotrophin-like cytokine
US7153827B1 (en) Vascular endothelial growth factor 2 and methods of use
US20040038275A1 (en) Human frezzled-like protein
EP0961832A1 (en) Human tumor necrosis factor receptor-like genes
CN106892982B (zh) 靶向IL-17和TNFα的新型融合多肽及其应用
CN114369171B (zh) 一种融合CXCR3和αFR抗体的嵌合抗原受体及其效应细胞和在治疗卵巢癌中的应用
US9943567B2 (en) Method for treating arthritis using IK factor or nucleic acid encoding IK factor
US6114503A (en) Human blue-light photoreceptor hCRY2
CN107619442B (zh) 一种重组抗TNF-α全人源单克隆抗体制剂
CN100436482C (zh) 长效人促红细胞生成素融合蛋白及其制备和纯化方法
CN116333055A (zh) 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
WO1999062934A1 (en) Interferon receptor hkaef92
CN115873127B (zh) 重组长效人生长激素融合蛋白及其制备方法和用途
US20240083959A1 (en) Deglycosylated lrg1 glycoprotein and lrg1 glycoprotein variant, and use thereof
CN117980323A (zh) R-spondin蛋白的重组变体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220819

Address after: Room 104, 1st Floor, Building 6, No. 58, Jinghai 5th Road, Beijing Economic and Technological Development Zone (Tongzhou), Tongzhou District, Beijing 101100 (Beijing Free Trade Pilot Zone High-end Industry Zone Yizhuang Group)

Patentee after: Beijing Huaao Xuande Biomedical Technology Co.,Ltd.

Address before: Room 1022, 10th Floor, Building 3, Yard 3, Zhonghe Road, Fengtai District, Beijing 100070

Patentee before: BEIJING SHUANGYIN BIOTECHNOLOGY Co.,Ltd.

Patentee before: Duan Haifeng

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250213

Address after: 100070 room 109, 1st floor, building 2, No.8 Haiying Road, Science City, Fengtai District, Beijing

Patentee after: BEIJING SHUANGYIN BIOTECHNOLOGY Co.,Ltd.

Country or region after: China

Address before: Room 104, 1st Floor, Building 6, No. 58, Jinghai 5th Road, Beijing Economic and Technological Development Zone (Tongzhou), Tongzhou District, Beijing 101100 (Beijing Free Trade Pilot Zone High-end Industry Zone Yizhuang Group)

Patentee before: Beijing Huaao Xuande Biomedical Technology Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right